Multivariable model for progression-free survival (N = 450∗ )
| Comparison . | Hazard ratio . | 95% CI . | P value (Pr > χ-square) . |
|---|---|---|---|
| Multivariable main effects model† | |||
| Treatment group, I / IR vs BR | 0.32 | 0.23-0.45 | <.0001 |
| Age, 5-year increase | 1.26 | 1.08-1.47 | .0036 |
| Beta-2 microglobulin, >5 vs <5 | 1.84 | 1.33-2.55 | .0002 |
| TP53 abnormality, yes vs no | 1.65 | 1.01-2.69 | .0447 |
| Karyotype abnormalities, 1 unit increase | 1.07 | 1.02-1.14 | .0124 |
| ZAP-70 methylation, >20% vs <20% | 0.68 | 0.5-0.94 | .0208 |
| Multivariable model, with interaction terms | |||
| Beta-2 microglobulin, >5 vs <5 | 1.82 | 1.31-2.52 | .0003 |
| Karyotype abnormalities, 1 unit increase | 1.07 | 1.01-1.13 | .0280 |
| Treatment group∗ at age of interaction | .0408 | ||
| I/IR vs BR at age = 65 | 0.20 | 0.11-0.37 | |
| I/IR vs BR at age = 70 | 0.28 | 0.20-0.41 | |
| I/IR vs BR at age = 75 | 0.40 | 0.27-0.57 | |
| I/IR vs BR at age = 80 | 0.55 | 0.31-0.98 | |
| Treatment group∗ TP53 abnormality interaction | .0006 | ||
| I/IR vs BR, no TP53 abnormality | 0.39 | 0.27-0.55 | |
| I/IR vs BR, TP53 abnormality | 0.07 | 0.03-0.18 | |
| Treatment group∗ ZAP-70 methylation interaction | .0002 | ||
| I/IR vs BR, ZAP-70 methylation <20% | 0.18 | 0.12-0.28 | |
| I/IR vs BR, ZAP-70 methylation >20% | 0.61 | 0.37-1.01 |
| Comparison . | Hazard ratio . | 95% CI . | P value (Pr > χ-square) . |
|---|---|---|---|
| Multivariable main effects model† | |||
| Treatment group, I / IR vs BR | 0.32 | 0.23-0.45 | <.0001 |
| Age, 5-year increase | 1.26 | 1.08-1.47 | .0036 |
| Beta-2 microglobulin, >5 vs <5 | 1.84 | 1.33-2.55 | .0002 |
| TP53 abnormality, yes vs no | 1.65 | 1.01-2.69 | .0447 |
| Karyotype abnormalities, 1 unit increase | 1.07 | 1.02-1.14 | .0124 |
| ZAP-70 methylation, >20% vs <20% | 0.68 | 0.5-0.94 | .0208 |
| Multivariable model, with interaction terms | |||
| Beta-2 microglobulin, >5 vs <5 | 1.82 | 1.31-2.52 | .0003 |
| Karyotype abnormalities, 1 unit increase | 1.07 | 1.01-1.13 | .0280 |
| Treatment group∗ at age of interaction | .0408 | ||
| I/IR vs BR at age = 65 | 0.20 | 0.11-0.37 | |
| I/IR vs BR at age = 70 | 0.28 | 0.20-0.41 | |
| I/IR vs BR at age = 75 | 0.40 | 0.27-0.57 | |
| I/IR vs BR at age = 80 | 0.55 | 0.31-0.98 | |
| Treatment group∗ TP53 abnormality interaction | .0006 | ||
| I/IR vs BR, no TP53 abnormality | 0.39 | 0.27-0.55 | |
| I/IR vs BR, TP53 abnormality | 0.07 | 0.03-0.18 | |
| Treatment group∗ ZAP-70 methylation interaction | .0002 | ||
| I/IR vs BR, ZAP-70 methylation <20% | 0.18 | 0.12-0.28 | |
| I/IR vs BR, ZAP-70 methylation >20% | 0.61 | 0.37-1.01 |
Patients with complete prognostic data not including IGHV data.
Variables considered for multivariable modeling were treatment group, age, sex, Rai stage, ECOG performance status, white blood cell count, beta-2 macroglobulin, lactate dehydrogenase, splenomegaly, del(11q), TP53 abnormality, number of karyotype abnormalities, and ZAP-70 methylation. Only significant variables (P < .05) are shown in this table.